NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Rapport Therapeutics, Inc. (RAPP) Stock Analysis

Rapport Therapeutics, Inc. (RAPP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RAPP

$25.06

−$4.31 (−14.67%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RAPP with… →

RAPP Key Statistics

As of Oct 21, 2026
Trading
Open
$29.91
Previous Close
$29.37
Day's Range
24.74–29.91
52-Week Range
23.75–52.93
Volume
2.15M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.22
Valuation
Market Cap
$1.20B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
60.12
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.03
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$111.48M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.98M
1-Year Return
−6.42%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
472.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RAPP closed at $25.06, −6.42% over 1 year.

Rapport Therapeutics, Inc. (RAPP) has a market capitalization of $1.20B.

In fiscal 2025, RAPP reported revenue of $0.00.

RAPP Stock Return by Calendar Year

Rapport Therapeutics, Inc. (RAPP) return since Jun 2024: what $10,000 became

1 year
$10,000 $9,358
−6.42%
Since Jun 2024
$10,000 $12,048
+20.48%

If you had invested $10,000 in Rapport Therapeutics, Inc. (RAPP) at the close on June 7, 2024, the earliest close on record here, it would have been worth $12,048 at the close on October 21, 2026: +20.48% in total, +8.18% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.40%
2025+71.03%
2024 (partial year)−14.71%

As of October 21, 2026.

RAPP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$111.48M—
2024$0.00−$78.31M—
2023$0.00−$34.79M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$125.10M−$111.48M—
2024$0.00—−$83.06M−$78.31M—
2023$0.00—−$36.18M−$34.79M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RAPP Valuation vs Biotechnology Median

Median of 608 stocks
MetricRAPPBiotechnology medianvs median
P/S ratio60.1213.304.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Rapport Therapeutics, Inc. (RAPP) is capitalised at $1.20B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 84 employees.

The most recent close on file for RAPP is $25.06, dated October 21, 2026. That is −$4.31 (−14.67%) against the previous close. The 52-week range on file runs from $23.75 to $52.93. The latest close sits 5.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $111.48M. Earnings per share on a trailing basis come to −3.03.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 60.12. On price-to-sales that is 4.5 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −6.42%. The stored price history starts on June 7, 2024, and the total return since then is +20.48%. The reported beta is 1.22. Daily returns over the trailing 2 years annualize to a volatility of 119.33%.

Growth & Income

No dividend is on file for RAPP.

The record holds one complete calendar year, 2025, which returned +71.03%. So far in 2026 the total return is −17.40%.

Peer Comparison

Rapport Therapeutics, Inc. (RAPP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rapport Therapeutics, Inc. RAPP $1.20B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Rapport Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Visit website →